{"doi":"10.1016/j.pnpbp.2011.03.019","title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","abstract":null,"journal":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","year":2011,"id":634506,"datarank":0.7894035283357329,"base_score":5.262690188904886,"endowment":5.262690188904886,"self_citation_contribution":0.7894035283357329,"citation_network_contribution":0.0,"self_endowment_contribution":0.7894035283357329,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":192,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":315140,"name":"Nancy Diazgranados","orcid":"0000-0002-7415-8455","position":1,"is_corresponding":false},{"id":396445,"name":"David A. Luckenbaugh","orcid":null,"position":2,"is_corresponding":false},{"id":1332173,"name":"Rodrigo Machado-Vieira","orcid":null,"position":3,"is_corresponding":false},{"id":1645667,"name":"Jacqueline Baumann","orcid":null,"position":4,"is_corresponding":false},{"id":1645670,"name":"Alan G. Mallinger","orcid":null,"position":5,"is_corresponding":false},{"id":230008,"name":"Carlos A. Zarate","orcid":"0000-0003-4442-7412","position":6,"is_corresponding":false},{"id":1645661,"name":"Lobna Ibrahim","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","abstract":"<h4>Background</h4>Ketamine rapidly improves depressive symptoms in patients with treatment-resistant major depressive disorder (MDD) who do not respond to multiple standard antidepressants. However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT).<h4>Methods</h4>This study compared 17 patients with treatment-resistant MDD who previously did not respond to ECT and 23 patients with treatment-resistant MDD who had not previously received ECT. All subjects received a single open-label infusion of ketamine (0.5 mg/kg). Patients were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (60 min before the infusion), as well as at 40, 80, 120, and 230 min after infusion.<h4>Results</h4>Depressive symptoms were significantly improved in the ECT-resistant group at 230 minutes with a moderate effect size (p < .001, d = 0.50, 95% C.I.: 0.21-0.80). At 230 minutes, the non-ECT exposed group showed significant improvement with a large effect size (p < .001, d=1.00, 95% C.I.: 0.71-1.29).<h4>Conclusion</h4>Ketamine appears to improve depressive symptoms in patients with MDD who had previously not responded to ECT. These preliminary results encourage further investigation with a larger sample size to determine effectiveness compared to other treatment-resistant patients with MDD.","is_dataset_classified":null,"base_score":5.262690188904886,"endowment":5.262690188904886,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21466832","pmcid":"PMC3100439","openalex_id":"https://openalex.org/W2002580140","authors":[],"funders":[{"funder_name":"Intramural NIH HHS","grant_id":"ZIA MH002857","title":null}],"total_grants":1,"fwci":17.0015,"citation_percentile":0.99572196,"influential_citations":0,"citation_trend":[{"year":2012,"count":12},{"year":2013,"count":26},{"year":2014,"count":22},{"year":2015,"count":26},{"year":2016,"count":14},{"year":2017,"count":10},{"year":2018,"count":13},{"year":2019,"count":10},{"year":2020,"count":18},{"year":2021,"count":11},{"year":2022,"count":8},{"year":2023,"count":7},{"year":2024,"count":5},{"year":2025,"count":3},{"year":2026,"count":3}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0278584611001126?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0278584611001126?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.pnpbp.2011.03.019","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21466832","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3100439","host_type":"repository"}],"fields_of_study":["Treatment of Major Depression","Electroconvulsive Therapy Studies","Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes"],"mesh_terms":["Adolescent","Adult","Aged","Depressive Disorder, Major","Major Depressive Disorder","Electroconvulsive Therapy","Female","Humans","Injections, Intravenous","Ketamine","Male","Middle Aged","Psychiatric Status Rating Scales","Socioeconomic Factors","Linear Models","N-Methylaspartate","Treatment Failure","Sample Size","Excitatory Amino Acid Antagonists","Young Adult"],"keywords":["Electroconvulsive therapy","Major depressive disorder","Ketamine","Treatment-resistant depression","Depression (economics)","Depressive symptoms","Internal medicine","Medicine","Rating scale","Psychology","Anesthesia","Psychiatry","Cognition"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T13:46:18.108039Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}